COYANasdaqPharmaceutical PreparationsFiscal year ends December 31
Coya Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$4.20−0.05 (-1.18%)
Close on Oct 19, 2026
- Market cap
- $98.52M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.16 (−33.96%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Coya Therapeutics, Inc. grew revenue 1793.8% to $8.02M over the twelve months to Jun 30, 2026.
Revenue
$8.02M
+1793.8% vs. a year earlier
Operating income
-$23.15M
TTM Q2 2026
EPS, diluted
-$1.07
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $98.52M
- P/E ratio
- –
- Price to sales
- 12.29
- Price to book
- 2.28
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $8.02M
- Net income
- -$21.67M
- EPS, diluted
- -$1.07
- Book value per share
- $1.84
- Diluted shares
- 23M
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
$8.02M+1793.8% YoY
Operating income
-$23.15M
Net income
-$21.67M
EPS, diluted
-$1.07
Reported periodTrailing twelve months